Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
Solid Tumor|Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations|Tenosynovial Giant Cell Tumor
DRUG: PLX7486 TsOH
Safety of PLX7486 as single agent as measured by adverse events and serious adverse events., 1 year|Area under the plasma concentration-time curve [AUC0-t, AUC0-inf], Area under the plasma concentration-time curve \[AUC0-t, AUC0-inf\] will be used to assess the pharmacokinetic profile of PLX7486., 1 year|Peak concentration (Cmax), Peak concentration (Cmax) will be used to assess the pharmacokinetic profile of PLX7486., 1 year|Time to peak concentration (Tmax), Time to peak concentration (Tmax) will be used to assess the pharmacokinetic profile of PLX7486., 1 year|Half life (t1/2), Half life (t1/2) will be used to assess the pharmacokinetic profile of PLX7486., 1 year|Terminal elimination rate constant (Kel), Terminal elimination rate constant (Kel) will be used to assess the pharmacokinetic profile of PLX7486., 1 year
Duration of response (DOR), Duration of response is defined as the number of days from the date of initial response (PR or better) to the date of first documented disease progression/relapse or death, whichever occurs first., 1 year|Progression-Free Survival (PFS), Progression-free survival (PFS) is defined as the number of days from start of therapy to the date of documented disease progression/relapse, whichever occurs first., 6 month|Overall Response Rate (ORR), 1year|Overall Survival (OS), 1 year
Part 1. Open-label, sequential PLX7486 TsOH single-agent dose escalation in approximately 60 patients with solid tumors.